Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Neuren appoints Chief Operating Officer

Neuren appoints Chief Operating Officer

18 July 2006: Neuren Pharmaceuticals (ASX: NEU) announced today the appointment of Dr Parmjot Bains to the position of Chief Operating Officer.

Dr Bains will be responsible for the operation of the clinical trial programs, ensuring overall responsibility for the budgets and milestones and also that all manufacturing, monitoring and reporting objectives are met. Currently Neuren has two clinical trials on track, with this planned to go to four during the 2007 year. Dr Bains will provide the overall coordination and management of this programme with the CMO, Dr Doug Wilson providing strategic input and the FDA regulatory interface.

Dr Bains’ previous role was leading a US$100 million division of Fonterra Co-operative Group Limited that researches, develops, markets and sells specialty and other products globally. Her previous positions included Biotech Business Development Manager responsible for new product development and IP/regulatory affairs.

Prior to that she worked at McKinsey and Company for four years based in Sydney. Dr Bains has also spent time with venture capital firm, Rubicon, and the World Health Organisation.

Dr Bains has completed a Masters of Philosophy at Cambridge University (UK) under a Commonwealth Scholarship and a Bachelor of Medicine and Surgery at Auckland University (NZ) where she was the highest ranked final year graduate, going on to work as a clinician at Sydney Children’s Hospital.

Mr David Clarke, Chief Executive Officer of Neuren commented: “On behalf of the Board we would like to welcome Parmjot to her position. Her exceptional experience in a broad range of management, science, medicine and finance will complement the variety of activities she will be overseeing.”

About Neuren Pharmaceuticals
Neuren Pharmaceuticals (ASX: NEU) is a biotechnology company developing novel therapeutics in the fields of neurotherapy and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition. Neuren has two lead candidates, Glypromate® and NNZ-2566, targeting a range of acute and chronic neurological conditions. Neuren has commercial and development partnerships, including Pfizer, the US Army’s Walter Reed Army Institute of Research and Metabolic Pharmaceuticals.

For more information, please visit Neuren’s website at www.neurenpharma.com

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

I Sing The Highway Electric: Charge Net NZ To Connect New Zealand

BMW is turning Middle Earth electric after today announcing a substantial contribution to the charging network Charge Net NZ. This landmark partnership will enable Kiwis to drive their electric vehicles (EVs) right across New Zealand through the installation of a fast charging highway stretching from Kaitaia to Invercargill. More>>

ALSO:

Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>

Earlier:

Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>

ALSO:

Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>

ALSO:

Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

ALSO:

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news